JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Posted by: admin Categories: Covid19

Ravindra Ganesh,¹

Colin F. Pawlowski,²

John C. O'Horo,³

Lori L. Arndt,⁴

Richard F. Arndt,⁵

Sarah Bell,⁶

Dennis M. Bierle,¹

Molly Destro Borgen,⁷

Sara Hanson,⁸

Alexander Heyliger,⁹

Jennifer L. Larsen,⁶

Patrick J. Lenehan,¹⁰

Robert Orenstein,¹¹

Arjun Puranik,²

Leigh L. Speicher,¹²

Sidna M. Tulledge-Scheitel,¹³

AJ Venkatakrishnan,²

Caroline G. Wilker,¹⁴

Andrew D. Badley,³ and

Raymund R. Razonable¹⁵

Published August 19, 2021
-

More info

BACKGROUND. Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.

METHODS. 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.

RESULTS. The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).

CONCLUSIONS. Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.

FUNDING. Mayo Clinic.

Supplemental material

Version history

Version
1
(August 19, 2021):
In-Press Preview

Source link

« Using Ruxolitinib to Target JAK1/2 in T-LBL May Prevent Treatment Resistance

Coronavirus (COVID-19) Update: August 24, 2021 »

facebook

Twitter

Google +1

Pinterest

You may also like...

Paracetamol and remdesivir Drug Interactions

What treatments are being used by hospitals to treat COVID?

Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Latest tweets:

Breathing Labs Follow

A company producing interfaces for breathing exercises, breathing games, and breathing entertainment. #health #physiotherapy #telemedicine

Breathing Labs @breathinglabs ·
2 Jul 2022

Breathing+ by Breathing Labs has passed peer review in a randomized controlled clinical trial that was recently published in SCI Q2 journal Pediatric Pulmonology. Research done by @bezmialem Full text is available in a link here: https://www.breathinglabs.com/clinical-trials/research-breathing-labs-and-nintendo-clinical-trial-is-published-in-journal-pediatric-pulmonology-sci-q2-impact-factor-3/?fbclid=IwAR2wNhSgurdbrrf3gzOOkHthgiWfXJ1x8RWvnMhkSo6fi33QPZEGzxzd6jM

Reply on Twitter 1543197052779257856 Retweet on Twitter 1543197052779257856 Like on Twitter 1543197052779257856 3 Twitter 1543197052779257856

Breathing Labs @breathinglabs ·
24 Jun 2022

BREAKING: @breathinglabs and @Nintendo clinical trial is published in journal Pediatric Pulmonology (SCI Q2, Impact Factor > 3), full text: https://breathinglabs.com/Nintendo%20&%20Breathing%20Labs%202022 #telemedicine #telehealth #mhealth

Reply on Twitter 1540459776005603329 Retweet on Twitter 1540459776005603329 2 Like on Twitter 1540459776005603329 3 Twitter 1540459776005603329

Breathing Labs @breathinglabs ·
5 Mar 2022

Clinical mouthpieces 10pcs packages are now available at 45€/50USD (shipping cost not included). Learn more: https://www.breathinglabs.com/latest-news/announcement-breathing-mouthpieces-for-clinical-and-professional-use-are-now-available/

Reply on Twitter 1500062790249328643 Retweet on Twitter 1500062790249328643 1 Like on Twitter 1500062790249328643 2 Twitter 1500062790249328643

Breathing Labs @breathinglabs ·
30 May 2021

BREATHING VR: Lately we are sourcing this VR headset for use in Breathing VR application. It allows easiest installation of both breathing+ headset cable, and USB charging cables, which is essential in professional use: https://www.banggood.com/VR-SHINECON-G5-VR-Glasses-3D-Virtual-Reality-Glasses-VR-Headset-For-iPhone-XS-11Pro-Mi10-p-1679808.html?rmmds=myorder&cur_warehouse=CN

Reply on Twitter 1399030891356241928 Retweet on Twitter 1399030891356241928 1 Like on Twitter 1399030891356241928 4 Twitter 1399030891356241928

Breathing Labs @breathinglabs ·
28 Nov 2020

Update: Each purchase of Breathing+ will now include three machine washable mouthpieces. Previous buyers will be supplied with those by their country representatives but will have to cover shipping costs. Please be patient while we arrange distribution. https://www.breathinglabs.com/latest-news/announcement-breathing-mouthpieces-for-clinical-and-professional-use-are-now-available/

Reply on Twitter 1332816878801199110 Retweet on Twitter 1332816878801199110 Like on Twitter 1332816878801199110 3 Twitter 1332816878801199110

Breathing Labs @breathinglabs ·
3 Nov 2020

Update: We moved servers + relocated all our games to our servers, please be patient while google reviews all that (showing unsafe website atm). Use duckduckgo or non-chromium browsers to reach our pages in the meantime. Everything ok + new product addons coming out in a month!

Reply on Twitter 1323709382857760768 Retweet on Twitter 1323709382857760768 1 Like on Twitter 1323709382857760768 1 Twitter 1323709382857760768

Breathing Labs @breathinglabs ·
19 Mar 2020

Registration and all functionalities at http://breathinglabs.com (and in our iOS and Android games) are fixed and fully working. If you find any issues -> [email protected]

Reply on Twitter 1240772601515032577 Retweet on Twitter 1240772601515032577 1 Like on Twitter 1240772601515032577 3 Twitter 1240772601515032577

Breathing Labs @breathinglabs ·
11 Sep 2019

We are back in stock with Breathing+, currently searching for VR supplier, and setting up mass production for toys and tens stimulation + in November we will be signing up new erasmus traineeships, research projects, bilateral, FP(eu), and asia-pacific ->[email protected]

Reply on Twitter 1171755394198319105 Retweet on Twitter 1171755394198319105 Like on Twitter 1171755394198319105 4 Twitter 1171755394198319105

Breathing Labs @breathinglabs ·
4 Aug 2019

BREAKING: Nintendo Co. Ltd (Japan) is implementing Breathing Games by @breathinglabs in FDA approved clinical trial for children with bronchiectasis: https://clinicaltrials.gov/ct2/show/NCT04038892

Reply on Twitter 1158073928050466817 Retweet on Twitter 1158073928050466817 1 Like on Twitter 1158073928050466817 3 Twitter 1158073928050466817

Breathing Labs @breathinglabs ·
29 May 2019

Notice to b2b partners: we are running late with some minor upgrade-> briefly running out of stock -> retail and b2b sale is closed until early october. To get a list of partners with stock to sell contact us at [email protected] Thanks, we'll go strong again in winter 💪

Reply on Twitter 1133731793650294784 Retweet on Twitter 1133731793650294784 Like on Twitter 1133731793650294784 Twitter 1133731793650294784

Load More

Home

How To Start

Q&A

Login

JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Latest tweets:

ABOUT

TECHNOLOGY

CLINICAL USE

COLLABORATION

REFERENCE

IN MEDIA

Home

How To Start

Products

Breathing+ Package

Toys Package

Q&A

Login

JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

You may also like...

Paracetamol and remdesivir Drug Interactions

What treatments are being used by hospitals to treat COVID?

Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Latest tweets:

ABOUT

TECHNOLOGY

CLINICAL USE

COLLABORATION

REFERENCE

IN MEDIA